PT-141 Spray

PT-141 Research & Scientific Overview

Jump to: Structure | Mechanism | Studies | Pharmacokinetics | Limitations | Lead Researcher | References

PT-141 Molecular Structure & Chemical Properties

PT-141, known chemically as bremelanotide, occupies an unusual position in the peptide literature: it is one of the few research peptides with a completed Phase 3 program behind it. The compound was derived from Melanotan II, an alpha-melanocyte-stimulating hormone (alpha-MSH) analog originally investigated as a pigmentation agent, after investigators observed unexpected effects on arousal circuits in early human testing[1]. Truncation produced a cyclic heptapeptide with reduced melanotropic activity and preferential affinity for centrally expressed melanocortin receptors; its lactam bridge locks the molecule into a rigid conformation that improves binding selectivity and resists enzymatic degradation.

)

Technical Specifications

The peptide retains the His-Phe-Arg-Trp core pharmacophore, the minimal sequence required for receptor recognition across the melanocortin family.

PT-141 Mechanism of Action

PT-141 acts as a non-selective melanocortin receptor agonist, with research attention concentrated on MC4R and MC3R subtypes expressed in hypothalamic and limbic tissue[1,2]. This makes it a centrally acting research tool, useful for isolating central contributions to arousal and autonomic signaling from vascular ones.

Primary Cellular Pathways

MC4R Agonism – Central Arousal Circuitry

MC4R is densely expressed in the paraventricular nucleus and medial preoptic area. Knockout work in mice established it as a necessary component of centrally regulated sexual response, with pharmacological blockade abolishing agonist-induced effects[2]. Downstream consequences documented in rodents include:

• Increased c-Fos immunoreactivity in hypothalamic nuclei after systemic administration[1]
• Activation of neurons that also take up tracer virus injected into peripheral erectile tissue[1]

PT-141 also binds MC3R with low-nanomolar affinity. Because it engages both subtypes, separating their respective contributions remains an open methodological problem requiring subtype-selective probes[4].

Dopaminergic Modulation

Preclinical work indicates that melanocortin activation in the medial preoptic area increases local dopamine release, a candidate downstream mediator of the behavioral effects seen in rodents[4,6]. PT-141 therefore sits upstream of a neurotransmitter system rather than acting on it directly.

MC1R Cross-Reactivity

The compound retains measurable affinity for MC1R, the receptor governing melanogenesis. This off-target activity is the mechanistic basis for pigmentation changes reported with repeated exposure, a known limitation of alpha-MSH-derived agonists[1].

Autonomic and Cardiovascular Signaling

Paraventricular MC4R neurons project to brainstem autonomic nuclei. Human studies document transient blood pressure increases with reciprocal heart rate reductions, attributed to central autonomic modulation rather than direct vascular action[9,12].

[CALLOUT BOX – Highlighted] Key Mechanistic Insight: PT-141’s central site of action is both its principal research value and its principal liability. The same MC4R population implicated in arousal signaling projects to autonomic control centers, making the cardiovascular response mechanistically inseparable from the primary effect rather than an incidental off-target artifact. [END CALLOUT BOX]

PT-141 Research Applications & Key Findings

Preclinical Behavioral Neuroscience

Rodent Models of Appetitive Behavior

The defining preclinical finding came from female rats, where PT-141 selectively increased solicitational behaviors without altering lordosis, pacing, or locomotor activity[3]. Key observations:

• Selectivity for appetitive over reflexive behavioral measures
• Effects reproduced by direct infusion into the lateral ventricle and medial preoptic area, supporting a central site of action[6]
• No generalized motor activation or altered reward perception[3]
• Comparable proceptive effects reported for the parent compound Melanotan II[5]

Reviews have consolidated these findings across rat and primate models[4].

Male Erectile Physiology Research

Studies in men used RigiScan instrumentation to quantify erectile response. Across a 0.3 to 10 mg subcutaneous range, investigators reported statistically significant, dose-dependent responses above 1.0 mg in healthy subjects and in men with an inadequate response to sildenafil[9,11]. The sponsor discontinued this line of work, and no Phase 3 program in men was completed.

Female Arousal and Desire Research

An early crossover study in 18 premenopausal women found more frequent reports of moderate or high desire versus placebo (P = 0.0114), though vaginal pulse amplitude, the objective measure, did not differ significantly[10]. That dissociation between subjective and physiological endpoints remains a methodological talking point.

The subsequent subcutaneous Phase 3 program (RECONNECT, two identically designed trials) reported significant improvements in desire and desire-related distress versus placebo, with mostly mild-to-moderate adverse events[13]; a 52-week open-label extension examined longer-term safety[14]. Effect sizes were statistically significant but modest, and no head-to-head comparison against the other approved agent for this indication has been published.

Metabolic Research

Two Phase 1 randomized controlled trials in women with obesity reported reductions in body weight and caloric intake versus placebo over short dosing periods, consistent with MC4R’s established role in energy balance[16].

[CALLOUT BOX – Highlighted] Important Context: Unlike most research peptides, PT-141 is not short on human data – the gap is route-specific. The FDA placed the mucosal administration program on clinical hold in 2007 after dose-dependent blood pressure elevations, and it was abandoned in 2008. The approved human evidence base applies exclusively to the reformulated subcutaneous route[12,15]. [END CALLOUT BOX]

PT-141 Pharmacokinetics & Metabolism

Absorption & Distribution

Absorption differs sharply by route, a distinction central to interpreting the literature[15]:

• Subcutaneous bioavailability approximately 100%; median Tmax near 1.0 hour
• Mean Cmax 72.8 ng/mL and AUC 276 hr*ng/mL at the 1.75 mg dose
• Concentrations rise less than dose-proportionally, plateauing around 7.5 mg
• Mucosal administration produced faster, considerably less predictable exposure[12]
• Protein binding approximately 21%; mean volume of distribution 25.0 L

Metabolism & Elimination

As a heptapeptide, PT-141 is not a cytochrome P450 substrate. Metabolism proceeds through hydrolysis of peptide bonds by non-specific peptidases, yielding fragments with no characterized melanocortin receptor activity[15]:

• Mean terminal half-life of approximately 2.7 hours (range 1.9-4.0 hours)
• Mean clearance of approximately 6.5 L/hr
• Limited hepatic contribution relative to most small molecules
• Observed effects outlast measurable plasma exposure, suggesting persistent receptor-level or downstream signaling

Excretion Pathways

Radiolabeled dose-recovery work established a predominantly renal route[15]:

• Approximately 64.8% recovered in urine, 22.8% in feces
• Short urinary clearance window, relevant to detection methodology
• No accumulation reported with the intermittent schedules studied

Common Model Organisms

• Rats – Primary model for behavioral and c-Fos mapping studies[1,3]
• Mice – Receptor-knockout work establishing MC4R necessity[2]
• Nonhuman primates and human subjects – Erectile physiology characterization and Phase 1-3 clinical work[1]

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

PT-141 inverts the usual research-peptide problem. Human data exist in quantity; the limitations lie in scope, magnitude, and route.

Route-Specific Evidence Gaps

• No completed late-stage program exists for mucosal administration. The FDA placed it on clinical hold in 2007 after dose-dependent blood pressure elevations, and the sponsor discontinued it in 2008[12]
• Mucosal exposure was rapid and variable, producing high plasma levels in a subset of subjects
• Published pharmacokinetic parameters derive from subcutaneous work and do not transfer across routes

Mechanistic Understanding Gaps

• Relative contributions of MC3R versus MC4R remain unresolved
• Dopaminergic mediation is inferred from correlative data, not established causally
• Receptor-level tolerance with repeated exposure is uncharacterized

Long-Term Safety Considerations

• Cardiovascular monitoring data extend only to intermittent, as-needed schedules
• Hyperpigmentation with repeated exposure is documented and attributed to MC1R activity
• No completed Phase 3 safety program exists in male populations

Regulatory & Competitive Sport Status

FDA Position

• Approved June 2019 as Vyleesi (bremelanotide injection, 1.75 mg subcutaneous) for acquired, generalized hypoactive sexual desire disorder in premenopausal women[15]
• No other route, dose form, or indication has FDA approval, including any mucosal presentation
• Research-grade PT-141 is an unapproved drug substance, not produced under approved-product controls

WADA Status

• Bremelanotide is not explicitly named on the current WADA Prohibited List; its approval by a governmental health authority means the S0 non-approved-substances category does not straightforwardly apply
• The List is expressly non-exhaustive, so unnamed substances may still fall within a listed class
• Status is revised annually and athletes remain under strict liability; verification via GlobalDRO or a national anti-doping organization is the appropriate step in any competitive context

Research Classification: PT-141 is available only for laboratory research use. It is not intended for human consumption, medical use, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

Lead Researcher Spotlight

Hunter Wessells, MD, FACS

Professor and Nelson Chair, Department of Urology University of Washington School of Medicine, Seattle, Washington, USA

Dr. Hunter Wessells conducted the foundational human investigations establishing melanocortin receptor agonism as a viable central mechanism for modulating sexual response. His 1998 double-blind crossover study showed that a synthetic melanotropic peptide could initiate erectile responses in men, directly motivating the structural work that produced PT-141[7]; a follow-up extended the observation to men with organic rather than psychogenic etiology[8]. He later led an NIH-funded program on neural melanocortin signaling and erectile function.

His research focus areas include:

• Central melanocortin signaling in erectile physiology
• Structure-activity relationships of melanotropic peptides
• Genetic susceptibility to diabetes-associated urological complications
• Urologic trauma and reconstructive surgery

Dr. Wessells has published more than 75 journal articles and book chapters.

Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to PT-141 research. Cenexa Labs has no affiliation with Dr. Hunter Wessells or the University of Washington, and this information does not constitute an endorsement of any products or services.

References

1. Molinoff, P.B., Shadiack, A.M., Earle, D., Diamond, L.E., & Quon, C.Y. (2003). PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96-102. PubMed
   
2. Van der Ploeg, L.H., Martin, W.J., Howard, A.D., Nargund, R.P., Austin, C.P., Guan, X., … & MacIntyre, D.E. (2002). A role for the melanocortin 4 receptor in sexual function. Proceedings of the National Academy of Sciences, 99(17), 11381-11386. PubMed
   
3. Pfaus, J.G., Shadiack, A., Van Soest, T., Tse, M., & Molinoff, P. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences, 101(27), 10201-10204. PubMed
   
4. Pfaus, J., Giuliano, F., & Gelez, H. (2007). Bremelanotide: An overview of preclinical CNS effects on female sexual function. The Journal of Sexual Medicine, 4(Suppl 4), 269-279. PubMed
   
5. Rossler, A.S., Pfaus, J.G., Kia, H.K., Bernabe, J., Alexandre, L., & Giuliano, F. (2006). The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat. Pharmacology Biochemistry and Behavior, 85(3), 514-521. PubMed
   
6. Pfaus, J.G., Sadiq, A., Spana, C., & Clayton, A.H. (2022). The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectrums, 27(3), 281-289. PubMed
   
7. Wessells, H., Fuciarelli, K., Hansen, J., Hadley, M.E., Hruby, V.J., Dorr, R., & Levine, N. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo controlled crossover study. The Journal of Urology, 160(2), 389-393. PubMed
   
8. Wessells, H., Gralnek, D., Dorr, R., Hruby, V.J., Hadley, M.E., & Levine, N. (2000). Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology, 56(4), 641-646. PubMed
   
9. Rosen, R.C., Diamond, L.E., Earle, D.C., Shadiack, A.M., & Molinoff, P.B. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research, 16(2), 135-142. PubMed
   
10. Diamond, L.E., Earle, D.C., Heiman, J.R., Rosen, R.C., Perelman, M.A., & Harning, R. (2006). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. The Journal of Sexual Medicine, 3(4), 628-638. PubMed
    
11. Safarinejad, M.R., & Hosseini, S.Y. (2008). Salvage of sildenafil failures with bremelanotide: A randomized, double-blind, placebo controlled study. The Journal of Urology, 179(3), 1066-1071. PubMed
    
12. Palatin Technologies, Inc. (2009). Announcement of subcutaneous bremelanotide trial in men, including comparative exposure and blood pressure data across delivery routes. Company announcement; peer-reviewed publication not available.
13. Kingsberg, S.A., Clayton, A.H., Portman, D., Williams, L.A., Krop, J., Jordan, R., Lucas, J., & Simon, J.A. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: Two randomized phase 3 trials. Obstetrics and Gynecology, 134(5), 899-908. PubMed
    
14. Simon, J.A., Kingsberg, S.A., Portman, D., Williams, L.A., Krop, J., Jordan, R., Lucas, J., & Clayton, A.H. (2019). Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstetrics and Gynecology, 134(5), 909-917. PubMed
    
15. Dhillon, S., & Keam, S.J. (2019). Bremelanotide: First approval. Drugs, 79(14), 1599-1606. PubMed
    
16. Spana, C., Jordan, R., & Fischkoff, S. (2022). Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes, Obesity and Metabolism, 24(6), 1084-1093. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. PT-141 is intended for laboratory research use only.